Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Source
Not yet recruiting
A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo
NCT07865312· Phase 3· Source
Enrolling by invitation
Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer
NCT07890311· Phase 2· Source
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516· Phase 2· Source
Not yet recruiting
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
NCT07691515· Phase 3· Source
Recruiting
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
NCT07583550· Phase 2· Source
Recruiting
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
NCT07406035· Phase 2· Source
Recruiting
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892· Phase 2· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Source
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· Phase 3· Source
Recruiting
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004· Phase 2· Source
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551· Phase 2· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Source
Not yet recruiting
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065· Source
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554· Phase 1· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Source
Recruiting
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07292714· Phase 2· Source
Recruiting
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976· Phase 3· Source
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Source
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Source
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Source
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Source
Active, not recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06789289· Phase 2· Source
Active, not recruiting
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
NCT06883630· Phase 1· Source
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996· Source
Active, not recruiting
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
NCT06702618· Phase 2· Source
Not yet recruiting
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
NCT06767540· Phase 3· Source
Active, not recruiting
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336· Phase 2· Source
Active, not recruiting
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883· Phase 2· Source
Active, not recruiting
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977· Phase 2· Source
Recruiting
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
NCT06496490· Phase 2· Source
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490· Phase 1/2· Source
Not yet recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599· Phase 3· Source
Active, not recruiting
SIM0718 Treatment of Asthma Clinical Study
NCT06488755· Phase 3· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Source
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Source
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· Phase 3· Source
Active, not recruiting
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
NCT06175351· Phase 1/2· Source
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· Phase 3· Source
Active, not recruiting
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398· Phase 3· Source
Recruiting
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
NCT04212494· Source
Active, not recruiting
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
NCT04379635· Phase 3· Source